Specific Biologics raises $35m Series A
Specific Biologics closed a US$35m Series A to advance its gene-editing candidate towards early clinical biomarker evidence in C9ORF72-associated ALS.
Gene editing has to move from a promising mechanism to evidence in patients. Specific Biologics’ latest financing is designed to support an early step in that transition.
What happened
Specific Biologics closed an oversubscribed US$35m Series A led by Hatteras Venture Partners. Investors include Lumira Ventures, adMare BioInnovations, Genesys Capital, BDC’s Life Sciences Venture Fund, DeepWork Capital and Seido Capital.
The financing will advance its lead Dualase candidate towards initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II trial for C9ORF72-associated ALS. The platform is designed to remove disease-associated DNA repeat expansions.
Why it matters
A treatment aimed at an underlying genetic driver has a different development challenge from one focused only on downstream symptoms. It must reach the relevant cells, make the intended edit and demonstrate a useful biological effect.
Early biomarker evidence could help assess that mechanism in patients. It would not, by itself, establish durable clinical benefit.
The bigger picture
For a biotechnology company, the value of a financing round depends partly on the evidence it can produce before the next major decision. Here, the capital is linked to a specific early clinical objective.
The programme will need to establish safety, delivery and activity as development progresses. The broader platform opportunity depends on those results, rather than on assuming that a repeat-removal approach will work equally well across different diseases.